Bafna Pharmaceuticals Ltd Share Price

Q: What is the share price of Bafna Pharmaceuticals Ltd today?

Bafna Pharmaceuticals Ltd share price as on 5 Dec 2025 is ₹0

Pharmaceuticals

NSE: BAFNAPH Small Cap ISIN: INE878I01022

As on 06 December 2025 at 02:03 IST

Stock Not Traded in NSE

Over 1 Month

-8.30%

Over 6 Months

98.48%

Over 1 Year

77.65%

Over 3 Years

41.51%

Bafna Pharmaceuticals Ltd Summary

Close ₹145.19

Open ₹145.19

High ₹145.19

Low ₹145.19

Volume 126

Net Turnover (in Cr) ₹0.0018

52Wk High ₹202.06

52Wk Low ₹69

52Wk High / Low

202.06

Bafna Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹343.47

EPS (TTM) 4.47

Book Value (BV) 38.56

Div. Yield -

P/E (TTM) 39.13

Price/Book Value 3.76

Delivery % -

Face Value 10

Key Ratios

PE Ratio 42.61

PB Ratio 2.09

EV to Sales 1.39

PEG Ratio -0.98

ROA 3.60

ROE 4.98

Debt-Equity 0.32

Net Profit Margin 4.37

Operating Profit Margin 9.59

Bafna Pharmaceuticals Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Total Revenue	42.73	44.01	78.50	66.10	87.30
Total Expenses	44.61	62.31	93.22	86.46	102.62
Profit Before Tax	-1.88	-18.29	-14.72	-20.36	-15.32
Profit After Tax	-1.88	-19.36	-16.91	-19.46	-15.14
Operating Profit After Depreciation	-1.79	-16.17	-7.77	-8.89	-2.36

Balance Sheet

Particulars (in ₹ Cr.)	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Fixed Assets	35	37.05	44.90	48.61	52.61
Total Non Current Assets	35.22	71	89.62	101.12	70.22
Total Current Assets	36.10	48.47	48.74	77.18	122.48
Total Assets	71.31	119.47	138.36	178.31	192.71
Total Shareholder's Fund	51.11	19.06	37.93	42.67	57.75

Cash Flow

Particulars (in ₹ Cr.)	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Net Cash From Operating Activities	-34.31	-1.79	-7.05	-0.95	0.91
Net Cash Used In Investing Activities	32.77	15.36	37.97	-5.42	-0.36
Net Cash Used In Financing Activities	7.30	-13.81	-30.63	6.31	-0.61

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	148.60	155.99	118.62	86.84	71.97
Total Expenses	142.30	148.64	107.01	79.47	66.14
Profit Before Tax	4.15	7.35	11.62	5.22	5.83
Profit After Tax	4.15	7.35	11.34	5.22	5.83
Operating Profit After Depreciation	9.03	9.64	13.65	8.17	6.57

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	58.78	41.98	41.73	38.85	35.97
Total Non Current Assets	68.35	53.91	42.27	39.26	36.80
Total Current Assets	84.73	93.77	87.31	50.88	49.67
Total Assets	153.08	147.68	129.58	90.14	86.47
Total Shareholder's Fund	84.81	80.84	73.45	61.96	56.77

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	22.14	9.48	4.95	9.73	-13.61
Net Cash Used In Investing Activities	-21.16	-15.05	-7.49	-6.54	-5.35
Net Cash Used In Financing Activities	1.06	-0.85	10.18	-4.81	12.28

Particulars (in ₹ Cr.)	2019-09	2019-06	2018-09	2018-06
Total Revenue	11.57	6.85	8.84	-
Total Expenses	11.94	9.71	8.66	-
Profit Before Tax	-0.54	-3.71	-1.22	-
Profit After Tax	-0.59	-2.13	-1.28	-3.52
Operating Profit after Depreciation	0.22	-2.56	0.15	-

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	35.47	34.62	39.06	33.19	40.32
Total Expenses	31.19	29.56	35.94	30.12	36.53
Profit Before Tax	3.13	3.38	1.32	0.95	2.61
Profit After Tax	3.12	3.39	1.31	0.95	2.62
Operating Profit after Depreciation	5.46	5.66	4.15	3.26	4.81

Bafna Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 145.19

S2 145.19

S3 145.19

Pivot 145.19

R1 145.19

R2 145.19

R3 145.19

Moving Average

20 SMA 167.22

50 SMA 159.85

100 SMA 129.72

200 SMA 103.31

Bafna Pharmaceuticals Ltd Corporate Actions

No available data

AGM Date: 14 Aug 2021

Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on June 25, 2021. Outcome Of Board Meeting ANNUAL GENERAL MEETING The 26th Annual General Meeting of the members of the Company is scheduled to be held on Saturday the 14th August 2021. We would like to inform you that, further to our announcement dated 25th June 2021 the Company's register of members will be closed from 07th August 2021 to 14th August 2021 (both days inclusive) for the purpose of annual general meeting. Security Code Type of security and paid up value Book closure Record date Purpose From to 532989 (BSE) BAFNAPH(NSE) Equity shares Rs.10/- paid up 07th August 2021 (Saturday) 14th August 2021 (Saturday) Both day inclusive N.A Annual General Meeting scheduled to be held on 14th August 2021 (As per BSE Announcement Dated on 26/7/2021) Please be informed that the 26th AGM of the Company was held on 14th August 2021 through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) at 11.00 a.m. IST. In this regard please find attached the summary of the proceedings of the AGM of the Company. The voting results of the 26th Annual General Meeting of the Company along with the Scrutinizer report will be shared shortly. The 26th Annual General Meeting of the Company was concluded at 12.00 Noon IST We request you to take the above information on your record (As Per BSE Announcement Dated on 8/14/2021 3:26:08 AM) Sub.:- Voting Results and scrutinizer report for the 26th AGM held on 14th August 2021 Ref.:- Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find attached voting results for the 26th AGM held on 14th August 2021 under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and scrutinizer report. Please take it in record. (As Per BSE Announcement Dated on 8/16/2021 7:04:53 AM)

AGM Date: 28 Jul 2022

AGM 28/07/2022 1. AUDITED FINANCIAL RESULTS Approval of audited financial results of the Company for the quarter and year ended 31st March 2022. Please find enclosed the following: 1. Audited financial statements (standalone) for the quarter and year ended 31st March 2022 along with Auditor's report for the said period 2. Declaration on Unmodified Opinion in the Auditors' Report for Financial Year ended March 31, 2022 2. ANNUAL GENERAL MEETING The 27th Annual General Meeting of the members of the Company is scheduled to be held on Thursday, 28th July 2022 at 12:00 Noon through video conferencing and other audio visual means. 3. To open wholly owned subsidiary of Bafna Pharmaceuticals Limited in Australia. (As Per BSE Announcement dated on 26.05.2022) We hereby inform you that 27th Annual General Meeting of the Company is scheduled to be held on Thursday, 28th July 2022. Further, pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Register of Beneficial Owners, Register of Members and Share Transfer Books of the Company shall remain closed from 22nd July 2022 to 28th July 2022 (both days inclusive) for the purpose of Annual General Meeting. (As Per BSE Announcement Dated on 05/07/2022) We wish to inform you that the 27th Annual general meeting of the Company will be held on Thursday 28th July 2022 at 11:00 am through Video-Conferencing. Pursuant to Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Annual Report of the Company for the financial year 2021 - 2022, which has been sent to the members of the Company through electronic mode. The Copy of the report and accounts of the Company for the financial year ended 31st March 2022 together with the Notice are also being uploaded on the Company's website www.bafnapharma.com (As Per BSE Announcement Dated on 06.07.2022) Please be informed that the 27th AGM of the Company was held on 28TH JULY 2022 through Video Conferencing ('VC')/ Other Audio Visual Means ('OAVM') at 11.00 a.m. IST. In this regard please find attached the summary of the proceedings of the AGM of the Company. The voting results of the 27th Annual General Meeting of the Company along with the Scrutinizer report will be shared shortly. The 27th Annual General Meeting of the Company was concluded at 11.30 A M We request you to take the above information on your record (As Per BSE Announcement dated on 28.07.2022) Bafna Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 Attached is the scrutinizer report of the AGM held on 28.07.2022 (As per BSE Announcement Dated on 29/07/2022)

AGM Date: 22 Sep 2023

AGM 22/09/2023 the 28th Annual General Meeting of the Members of the Company will be held on Friday, September 22, 2023, at 10:25 am IST, through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). the 28th Annual General Meeting of the Members of the Company will be held on Friday, September 22, 2023, at 10:25 am IST, through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). (As Per BSE Announcement Dated on 11.08.2023) We wish to inform that 28th Annual General Meeting (AGM) of the Company was held today i.e., Friday, September 22, 2023, through Video Conferencing mode and business mentioned in the notice dated August 11, 2023, was transacted by the members of the Company. In this connection, we have enclosed summary of proceedings of the AGM as required under the Regulation 30 read with part A of Schedule III of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 22/09/2023)

AGM Date: 25 Sep 2024

AGM 25/09/2024 Outcome / Proceedings of the 29th Annual General Meeting of the Company held on September 25, 2024 (As Per BSE Announcement dated on 25.09.2024)

AGM Date: 19 Sep 2025

The 30th Annual General Meeting (AGM) of the Company will be held on Friday, September 19, 2025, at 10:00 A.M (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). We hereby inform that the 30th Annual General Meeting of the Company (AGM) is scheduled to be held on Friday, September 19, 2025 at 10.00 A.M through Video Conferencing (VC) / Other Audio Visual Means (OAVM). (As Per BSE Announcement Dated on:21.08.2025) We herewith enclose the Outcome / Proceedings of the 30th Annual General Meeting of the Company held on September 19, 2025. (As per BSE Announcement Dated on 19/09/2025)

Bafna Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,818.60	₹4,36,343.06
Divis Laboratories Ltd	₹6,470.60	₹1,71,774.10
Torrent Pharmaceuticals Ltd	₹3,801.65	₹1,28,659.33
Cipla Ltd	₹1,521.20	₹1,22,878.16
Dr Reddys Laboratories Ltd	₹1,277	₹1,06,581.13

Bafna Pharmaceuticals Ltd Top Mutal Funds Invested

No data available

Bafna Pharmaceuticals Ltd News

Bafna Pharmaceuticals to convene board meeting

On 11 November 2025

07 Nov 2025, 01:42 pm

Bafna Pharmaceuticals AGM scheduled

On 19 September 2025

20 Aug 2025, 04:01 pm

Bafna Pharmaceuticals to discuss results

On 12 August 2025

09 Aug 2025, 03:14 pm

Bafna Pharmaceuticals to table results

On 26 May 2025

21 May 2025, 10:24 am

Bafna Pharmaceuticals announces board meeting date

On 6 February 2025

28 Jan 2025, 05:34 pm

Bafna Pharmaceuticals Ltd Stock Analysis

Annual revenue for Bafna Pharmaceuticals Ltd decreased by 4.74% to ₹148.60 crore in FY 2025 from ₹155.99 crore in FY 2024.
Annual Net Profit for Bafna Pharmaceuticals Ltd decreased by 43.49% to ₹4.15 crore in FY 2025 from ₹7.35 crore in FY 2024.
Promoter Shareholding in Bafna Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 75% in June 2025 to 75% in September 2025.
Bafna Pharmaceuticals Ltd delivered a 1-year return of 77.65% compared to the Nifty 50, which provided a return of 6.40% as of the last trading session.
Bafna Pharmaceuticals Ltd share price moved down by 100.00% from its previous close of INR ₹145.19. The latest Bafna Pharmaceuticals Ltd share price is INR ₹0.
Bafna Pharmaceuticals Ltd share price today has been at a low of 145.19 and a high of 145.19. Over the past 52 weeks, the Bafna Pharmaceuticals Ltd share price has seen a low of 69 and a high of 202.06.